Targets › INSULIN
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.
Open in Phaseline: the race on INSULIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Allogenic Human Islet Cells Intraportal infusion of insulin-producing pancreatic islet cells for metabolic restoration | INSULIN, GCGR | Phase 2 | Type 1 Diabetes Mellitus; Diabetes Mellitus, Type 1 | Aug 2027 |
Type 1 Diabetes Mellitus (1) Diabetes Mellitus, Type 1 (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.